DOCK1: A Drug Target / Disease Biomarker (G1793)

Target Name: DOCK1

NCBI ID: G1793

DOCK1

DOCK1: A Drug Target / Disease Biomarker

DOCK1, a protein that plays a crucial role in the development and progression of many diseases, has been identified as a potential drug target or biomarker. Its functions and interactions with other proteins have been extensively studied, and its potential as a drug target have been evaluated in various preclinical and clinical studies.

DOCK1 is a member of the DOCK family, which includes several similar proteins that play a common role in intracellular signaling. These proteins are involved in the regulation of various cellular processes, including cell growth, apoptosis, angiogenesis, and cell-cell adhesion. DOCK1 is specifically involved in the regulation of cell adhesion and in the development of various diseases.

One of the key functions of DOCK1 is its role in cell adhesion. DOCK1 helps to regulate the interactions between cells and the formation of tight junctions, which are a type of cell-cell adhesion structure. These interactions between cells are critical for various cellular processes, including cell signaling, and are often disrupted in diseases such as cancer, where abnormal cell-cell adhesion can contribute to tumor progression and the development of invasive and metastatic tumors.

In addition to its role in cell adhesion, DOCK1 is also involved in the regulation of cell survival and apoptosis. DOCK1 has been shown to play a role in the regulation of cell apoptosis, which is a natural process that helps to remove damaged or dysfunctional cells from the body. DOCK1 has also been shown to contribute to the regulation of cell survival by preventing apoptosis and promoting the survival of cells under stress.

The potential drug target for DOCK1 is based on its involvement in the regulation of cell adhesion and its role in the regulation of cell survival and apoptosis. Drugs that target DOCK1 have been shown to be effective in various preclinical studies in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In preclinical studies, drugs that target DOCK1 have been shown to be effective in treating various diseases, including cancer. For example, studies have shown that inhibiting DOCK1 can be an effective way to treat various types of cancer, including breast cancer, lung cancer, and colorectal cancer. These drugs work by inhibiting the activity of DOCK1 and preventing it from regulating the interactions between cells and the formation of tight junctions.

In addition to its potential as a cancer drug, DOCK1 has also been identified as a potential biomarker for various diseases. The regulation of cell adhesion and the regulation of cell survival and apoptosis are critical processes that are involved in the development and progression of many diseases. Therefore, the regulation of DOCK1 activity could be an attractive biomarker for the diagnosis and prognosis of various diseases.

In clinical trials, drugs that target DOCK1 have been shown to be effective in treating various types of diseases, including cancer. For example, studies have shown that inhibiting DOCK1 with small interfering RNA (siRNA) can be an effective way to treat various types of cancer, including breast cancer, lung cancer, and colorectal cancer. These drugs work by introducing a small interfering RNA that targets the DOCK1 gene and inhibiting its activity.

In conclusion, DOCK1 is a protein that plays a crucial role in the development and progression of many diseases. Its functions and interactions with other proteins have been extensively studied, and its potential as a drug target or biomarker have been evaluated in various preclinical and clinical studies. The regulation of cell adhesion and the regulation of cell survival and apoptosis are critical processes that are involved in the development and progression of many diseases, and the regulation of DOCK1 activity could be an attractive biomarker

Protein Name: Dedicator Of Cytokinesis 1

Functions: Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Along with DOCK1, mediates CRK/CRKL regulation of epithelial and endothelial cell spreading and migration on type IV collagen (PubMed:19004829). Functions as a guanine nucleotide exchange factor (GEF), which activates Rac Rho small GTPases by exchanging bound GDP for free GTP. Its GEF activity may be enhanced by ELMO1 (PubMed:8657152)

The "DOCK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DOCK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets